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Background: Atypical fibroxanthoma (AFX) represents an
uncommon skin tumor typically occurring on sun-damaged skin of the
elderly. Histopathologic variants include spindled, clear cell, osteoid,
osteoclastic, chondroid, pigmented, granular cell and myxoid lesions.
To date, an atypical lymphoid infiltrate, including CD30-positive large
cells mimicking lymphomatoid papulosis, has not been described in
association with AFX.
Methods: The clinical and histopathological characteristics of two
AFX cases inciting an atypical lymphoid infiltrate, along with
immunohistochemical profiles and T-cell receptor gamma (TCRγ) gene
rearrangement results, were reviewed.
Results: Lesions in both cases occurred as solitary nodules in elderly
patients. Microscopically, both lesions showed a cellular proliferation
composed of pleomorphic spindle cells, associated with a prominent
intralesional atypical lymphoid infiltrate. The spindle cells expressed
CD10 but lacked the expression of S-100, cytokeratins and muscle mark-
ers, thereby confirming the diagnosis of AFX. CD30 highlighted a signif-
icant subset of large mononuclear cells in the lymphoid infiltrate of one
case. TCRγ gene rearrangement analyses were negative for both cases.
Conclusion: An atypical lymphoid infiltrate, including the one
resembling lymphomatoid papulosis, associated with AFX has not been
previously described. It is important to recognize the reactive nature of
the infiltrate to avoid a misdiagnosis of lymphoma.
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Atypical fibroxanthoma (AFX) represents a cuta-
neous neoplasm that typically occurs on sun-
damaged skin of elderly patients. It usually follows
a non-metastatic course, presumably because of its
superficial location, and is considered a superficial
variant of pleomorphic sarcoma (formerly malignant
fibrous histiocytoma1).
Microscopically, AFX is characterized by atyp-
ical spindled cells arranged haphazardly or in a
vaguely fascicular pattern. The tumor cells may be
multinucleated and may exhibit nuclear pleomor-
phism and frequent mitoses.2 Several variants have
been described, including spindled,3 clear cell,4– 7
osteoid,8 osteoclast-like giant cell,9– 12 chondroid,9
pigmented,13 granular cell14– 16 and myxoid types.17
Herein, we present two cases of AFX accompanied
by a prominent lymphoid infiltrate containing
atypical lymphocytes. One case possessed many
CD30-positive atypical large mononuclear cells and
thus mimicked lymphomatoid papulosis (LyP) or
anaplastic large-cell lymphoma.
Case 1
A 91-year-old male with no previous history of skin
cancer presented with a large, slightly exophytic
growing lesion on the left parietal scalp for 6 months.
The initial biopsy performed at an outside institution
was interpreted as AFX. Two months later, the lesion
had partially regressed, leaving a faintly pink and
8
AFX and lymphomatoid reaction
Fig. 1. Case 1: A) Recurrent atypical fibroxanthoma (AFX) arising
on the left parietal scalp, measuring 2.8 × 3.5 cm. B) Clinical
evidence of regression is observed adjacent to the tumor.
non-indurated plaque. On physical examination, a
slightly elevated plaque measuring 2.8 × 3.5 cm was
noted on the parietal scalp (Fig. 1). The lesion was
re-excised and examined. No additional treatment
was provided. After one and a half year follow up, he
was free of disease with no evidence of recurrence or
metastasis.
Case 2
A 68-year-old female had a lesion on the left thigh
for 5 years. A partial biopsy was performed at an
outside institution in 2007, and a ‘reactive process’
was favored. After a hip fracture, the patient noticed
that the lesion became red and itchy with possible
vesicles. She was otherwise healthy with no history
of lymphoma or leukemia. On physical examination,
there was a 1 cm tan to red nodule on her left thigh.
A shave biopsy was performed.
Materials and methods
The available specimens for both cases were exam-
ined. Five micron sections were prepared from
formalin-fixed, paraffin-embedded tissue blocks, and
stained with hematoxylin and eosin for light micro-
scopic examination. Immunohistochemical stud-
ies were conducted using monoclonal and poly-
clonal antibodies, including S-100 protein, melan-A,
NKI-C3, cytokeratins AE1/AE3, CAM 5.2, high
molecular weight cytokeratin K903, factor XIIIa,
vimentin, smooth muscle actin, desmin, CD3, CD10,
CD15, CD20, CD30, CD34, CD68 and ALK-1.
Appropriate positive and negative controls were run
in parallel with each immunohistochemical stain.
Both cases were evaluated for T-cell receptor
gamma (TCRγ) gene rearrangement (GR), and case 1
was also evaluated for immunoglobulin heavy chain
GR. Genomic DNA was extracted and amplified by
multiplex polymerase chain reaction using two sets
of primers: (i) 5′-fluorescent end-labeled primers that
anneal to conserved sequences in the V and J regions
of the TCRγ gene (TCRγGR) or the three conserved
framework regions of the IGH gene (FR1, FR2 and
FR3) (B-cell immunoglobulin heavy chain GR) and
(ii) primers that target the human beta-globin gene.
The amplified products were then subjected to frac-
tionation using capillary electrophoresis followed by
detection through differential fluorescence emission.
Results
Case 1 showed a large dermal malignant spindle
cell neoplasm surrounded by a brisk and atypical
lymphoid infiltrate (Fig. 2). The spindle cells had
hyperchromatic and pleomorphic nuclei with a few
multinucleated giant cells. As summarized in Table 1,
immunohistochemically the tumor cells were strongly
positive for vimentin and CD68, but were negative
for S-100, melan-A, cytokeratin AE1/AE3, K903
and muscle-specific actin. A subset of the tumor cells
was positive for CD10, but negative for all other
lymphoid markers, including CD20. Procollagen,
a marker that holds greater lineage specificity,
was not available in our immunohistochemistry
laboratory.18 The surrounding lymphoid infiltrate
consisted of a mixture of small to intermediate-sized
CD3-positive T cells and CD20-positive B cells.
Scattered CD30-positive large mononuclear cells
(approximately ×2–3, the size of normal small
lymphocytes), with dot-like golgi and membranous
patterns were also present. The CD30-positive lym-
phocytes did not express ALK-1 or CD15. TCRγ
gene and immunoglobulin heavy GR studies were
negative. The findings supported a diagnosis of AFX
with a reactive (lymphomatoid) lymphocytic host
response. A repeat biopsy showed residual AFX with
an adjacent loose fibromyxoid and fibrous stroma, the
latter features correlating with the clinical impression
of regression.
Case 2 showed a dermal-based atypical spin-
dled and epithelioid cell proliferation with surface
ulceration (Fig. 3). The tumor cells had pleomor-
phic nuclei with abundant eosinophilic cytoplasm.
Scattered mitotic figures were present. Similar to
case 1, the tumor was outlined by a brisk lymphoid
infiltrate, but accompanied by conspicuous clusters
of large lymphocytes and eosinophils. Immunostains
(Table 1) showed that the tumor cells were strongly
positive for CD10 and weakly positive for NKI-C3.
There was focal and weak reactivity for smooth
muscle actin and a very focal CD34 positivity. The
tumor cells were negative for cytokeratins, S-100, fac-
tor XIIIa, desmin, CD3, CD20, CD30 and CD68.
CD30 highlighted many large activated lymphocytes,
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Fig. 2. Case 1: A) Tissue sections reveal a large dermal spindle cell neoplasm composed of atypical spindle cells haphazardly and in fascicles with
interspersed multinucleated giant cells (H&E, ×40). B) The hyperchromatic and pleomorphic malignant spindle cells with rare multinucleated
giant cells, surrounded by a brisk and atypical lymphoid infiltrate (H&E, ×400). C) A small subset of large atypical lymphoid cells that expressed
CD30 (IHC, ×400). D) The spindled and pleomorphic tumor cells decorated with CD10 (×400). E) and F) Stromal regression is evident,
adjacent to the atypical fibroxanthoma (AFX), corresponding to the clinical presentation in Fig. 1B; note in Fig. 2F the tumor in the upper left
corner and regression on the right and below the tumor (H&E, ×100 each). H&E, hematoxylin and eosin stain; IHC, immunohistochemistry.
which did not react with ALK-1 or CD15. A TCRγ
GR was negative for clonality. A diagnosis of superfi-
cial pleomorphic sarcoma compatible with AFX with
an associated lymphomatoid response was rendered.
Discussion
AFX is presently considered a low-grade sarcoma1
that has potential for local persistence19,20 but
rarely metastasizes.21,22 AFX typically arises on sun-
damaged skin of elderly patients but may rarely occur
on other sites.23,24 The histopathologic diagnosis of
AFX can sometimes be challenging. The diagnosis
of AFX is one of exclusion and requires the use
of a panel of immunohistochemistry to rule out
other cutaneous spindled malignancies, including
sarcomatoid squamous cell carcinoma (SCC), spindle
cell melanoma and leiomyosarcoma. For both of our
cases, the immunophenotype of the tumor cells was
consistent with AFX.
Interestingly, our examples of AFX elicited a
robust lymphoid infiltrate with a variable density
of atypical CD30-positive activated lymphocytes.
One of our cases simulated LyP. CD15 and ALK-1
negativity suggested that systemic anaplastic large
cell lymphoma or cutaneous Hodgkin’s lymphoma
was unlikely. We consider the possibility of a
cutaneous CD30-positive lymphoproliferative disor-
der arising concurrently with AFX as a possible
diagnosis. However, given the negative TCRγGR
result, the lack of aberrant T-cell immunophenotype,
the absence of a past history of a lymphoproliferative
10
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Table 1. Immunostain results for the atypical spindled and
pleomorphic tumor cells and the lymphoid infiltrate in the AFX cases









S-100 − NA − NA
Melan-A − NA ND NA
NKI-C3 ND NA + (w) NA
Factor XIIIa ND NA − NA
Smooth muscle actin ND NA + (w) NA
Muscle-specific actin − NA ND NA
Desmin ND NA − NA
Vimentin + NA ND NA
Keratin cocktail − NA − NA
K903 − NA ND NA
CD34 ND NA + (f, w) NA
CD68 + NA − NA
CD10 + (s) − + −
CD20 − + (s) − + (s)
CD3 − + (s) − + (s)
CD15 − − − −
CD30 − + (s∗) − + (s∗∗)
ALK-1 − − − −
NA, not applicable; ND, not done; f, focal; s, subset of cells (few∗;
many∗∗); w, weak.
disorder and the lack of concomitant or subsequent
clinical features compatible with lymphoma, a reac-
tive (lymphomatoid) infiltrate associated with AFX
was favored.
Spontaneous regression represents a known phe-
nomenon associated with cutaneous tumors. It
has been described with keratoacanthoma,25– 28
basal cell carcinoma,29,30 Merkel cell carcinoma,31
lymphoma,32 halo nevus28 and melanoma.33 We
suspect that the observation of a lymphomatoid infil-
trate in our two AFX cases represents a regressive
phenomenon. In fact, for case 1, there was evidence
of regression following the initial biopsy. Recently,
Stefanato et al.34 reported a small series of patients
with AFX showing microscopic features of regres-
sion, such as a variable amount of sclerotic collagen
and lymphoplasmacytic infiltrates. However, they
did not observe an atypical lymphoid infiltrate har-
boring large activated lymphocytes in their study. In
contrast, we did not observe hyalinization or sclerosis
in either patient’s tumor. To our knowledge, this is
the first report of AFX with regression character-
ized by an atypical lymphoid infiltrate containing
prominent enlarged CD30-positive lymphocytes.
CD30 antigen is a 120-kDa transmembrane recep-
tor that belongs to the tumor necrosis factor (TNF)
superfamily and displays restricted expression in the
Fig. 3. Case 2: A) Tissue sections display epidermal ulceration overlying a dermal infiltrate of cytologically atypical spindled and multinucleated
cells with abundant eosinophilic cytoplasm admixed with many lymphocytes and eosinophils (H&E, ×40). B) The tumor cells have abundant
eosinophilic cytoplasm, with a surrounding infiltrate of lymphocytes and clusters of large lymphocytes (H&E, ×200; inset: H&E, ×400).
C) The large atypical lymphoid cells are in close association with the malignant spindled and multinucleated cells and express CD30 (H&E,
×400; inset: IHC, ×400). D) The atypical spindled and multinucleated tumor cells label for CD10. (IHC, ×400). H&E, hematoxylin and
eosin stain; IHC, immunohistochemistry.
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subpopulations of activated T or B-lymphocytes.35,36
The expression of CD30 antigen is the hallmark of a
group of primary cutaneous CD30-positive T-cell
lymphoproliferative disorders, including LyP and
anaplastic large-cell lymphoma.37,38 It can also be
observed in cases of Hodgkin’s lymphoma.39 How-
ever, the presence of CD30-positive large cells is not
unique to primary cutaneous CD30-positive lym-
phoproliferative disorders, and can be seen in a vari-
ety of reactive conditions, including arthropod bite
reaction, viral infection or pityriasis lichenoides.40
CD30-positive large lymphoid cells in these condi-
tions are usually reactive T-lymphocytes and do not
represent a lymphoproliferative process. Similarly,
the presence of CD30-positive large lymphocytes
in our AFX cases is considered a reactive phe-
nomenon, given their intimate association with the
tumor and resemblance to a lymphomatoid reac-
tion. Similar observations have been reported in
other non-melanocytic skin proliferations, includ-
ing atypical squamous proliferations.41,42 This phe-
nomenon was first described in a case where multiple
keratoacanthoma-like lesions arose in close proxim-
ity to classic lesions of LyP.41 The authors postulated
that the keratoacanthoma-like lesions represented
a reactive change induced by atypical lympho-
cytes. Cespedes et al. described two cases of atypical
CD30-positive lymphocytic proliferation in close
association with keratoacanthoma and SCC.42 The
etiology is not well understood. Some authors suggest
that the atypical lymphoid infiltrate is a direct cause
of a secondary squamous proliferation as a result of
lymphocytes producing cytokines, epidermal growth
factor-like substances or other molecules that induce
epidermal proliferation.42 Other authors speculate
that the CD30-positive lymphomatoid infiltrate may
be a secondary reaction to squamous proliferation
rather than the inciting primary event.43,44 For our
two AFX cases, we suspect that the lymphoma-
toid infiltrate is a secondary inflammatory response
to the AFX and therefore may reflect early tumor
regression. The phenomenon of an associated lym-
phomatoid reaction seems to be uncommon. In the
reported large series of AFX, there is no mention of
it.2,20,45
In summary, we present two cases of AFX
associated with an atypical lymphomatoid infil-
trate possessing enlarged CD30-positive lym-
phocytes. Clinicopathologic correlation supported
interpretation as a lymphomatoid reaction to AFX,
which we suspect represents a form of tumor regres-
sion. It is important to be aware of this phenomenon
in order to prevent an erroneous diagnosis of
cutaneous lymphoma and unnecessary anxiety and
clinical workup for the patient.
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